IS4343A - Einstofna offitu (Ob) prótín - Google Patents

Einstofna offitu (Ob) prótín

Info

Publication number
IS4343A
IS4343A IS4343A IS4343A IS4343A IS 4343 A IS4343 A IS 4343A IS 4343 A IS4343 A IS 4343A IS 4343 A IS4343 A IS 4343A IS 4343 A IS4343 A IS 4343A
Authority
IS
Iceland
Prior art keywords
monocular
obesity
protein
monocular obesity
Prior art date
Application number
IS4343A
Other languages
English (en)
Icelandic (is)
Inventor
Campfield Arthur
Devos René
Guisez Yves
Pascal Sebastian Bailon Dr.
Original Assignee
F. Hoffman-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffman-La Roche Ag filed Critical F. Hoffman-La Roche Ag
Publication of IS4343A publication Critical patent/IS4343A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
IS4343A 1995-05-05 1996-05-03 Einstofna offitu (Ob) prótín IS4343A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43577795A 1995-05-05 1995-05-05
US48462995A 1995-06-07 1995-06-07

Publications (1)

Publication Number Publication Date
IS4343A true IS4343A (is) 1996-12-09

Family

ID=27030682

Family Applications (1)

Application Number Title Priority Date Filing Date
IS4343A IS4343A (is) 1995-05-05 1996-05-03 Einstofna offitu (Ob) prótín

Country Status (35)

Country Link
US (1) US6025325A (hu)
EP (1) EP0741187A2 (hu)
JP (1) JP3244627B2 (hu)
KR (1) KR100219970B1 (hu)
CN (1) CN1157290A (hu)
AR (1) AR003087A1 (hu)
AU (1) AU688210B2 (hu)
BG (1) BG62975B1 (hu)
BR (1) BR9602166A (hu)
CA (1) CA2175298A1 (hu)
CZ (1) CZ129796A3 (hu)
DE (1) DE741187T1 (hu)
ES (1) ES2093593T1 (hu)
GR (1) GR960300075T1 (hu)
HR (1) HRP960213A2 (hu)
HU (1) HU220093B (hu)
IL (1) IL118059A0 (hu)
IS (1) IS4343A (hu)
MA (1) MA23856A1 (hu)
MY (1) MY132189A (hu)
NO (1) NO961796L (hu)
NZ (1) NZ286466A (hu)
OA (1) OA10362A (hu)
PE (1) PE50897A1 (hu)
PL (1) PL186568B1 (hu)
RO (1) RO117177B1 (hu)
RU (1) RU96109211A (hu)
SG (1) SG49337A1 (hu)
SK (1) SK56996A3 (hu)
SV (1) SV1996000030A (hu)
TN (1) TNSN96066A1 (hu)
TR (1) TR199600357A2 (hu)
TW (1) TW464655B (hu)
UY (1) UY24219A1 (hu)
YU (1) YU26596A (hu)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE238417T1 (de) 1991-11-04 2003-05-15 Inst Genetics Llc Rekombinante knochenmorphogenetische protein heterodimere, zusammensetzungen und verfahren zur verwendung
US6479055B1 (en) * 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
US6001968A (en) * 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6471956B1 (en) 1994-08-17 2002-10-29 The Rockefeller University Ob polypeptides, modified forms and compositions thereto
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
US6048837A (en) * 1994-08-17 2000-04-11 The Rockefeller University OB polypeptides as modulators of body weight
US6124448A (en) * 1994-08-17 2000-09-26 The Rockfeller University Nucleic acid primers and probes for the mammalian OB gene
US6936439B2 (en) * 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
US20030040467A1 (en) * 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
AU769250B2 (en) * 1995-12-27 2004-01-22 Genentech Inc. OB protein derivatives having prolonged half-life
DE69632546T2 (de) * 1995-12-27 2005-06-30 Genentech, Inc., South San Francisco Ob proteinderivate mit verlängerter halbwertzeit
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
US7074397B1 (en) * 1996-01-08 2006-07-11 Genentech, Inc. Method for enhancing proliferation or differentiation of a cell using ob protein
US20050019325A1 (en) 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
US6541604B1 (en) 1996-01-08 2003-04-01 Genentech, Inc. Leptin receptor having a WSX motif
US5831017A (en) * 1996-01-25 1998-11-03 Eli Lilly And Company Obesity protein analog compounds and formulations thereof
US7067472B1 (en) * 1996-06-04 2006-06-27 The Scripps Research Institute Diagnostic and therapeutic methods related to regulating energy mobilization with OB protein and OB antibodies
US6001816A (en) * 1996-06-20 1999-12-14 Merck & Co., Inc. Gene therapy for leptin deficiency
US20060205660A1 (en) * 1996-06-20 2006-09-14 Sauvage Frederic D OB protein-immunoglobulin chimeras
US20030036629A1 (en) * 1997-12-12 2003-02-20 Barry Foster Novel tgf-beta protein purification methods
US6656906B1 (en) 1998-05-20 2003-12-02 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
US7169889B1 (en) * 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
PE20010288A1 (es) 1999-07-02 2001-03-07 Hoffmann La Roche Derivados de eritropoyetina
CZ299516B6 (cs) * 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
WO2001096565A2 (en) * 2000-06-16 2001-12-20 Asterion Limited Binding agents: chimeric ligand/receptor proteins
CN1406131A (zh) * 2000-12-25 2003-03-26 株式会社资生堂 活化交感神经的香料组合物
US6867183B2 (en) * 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
EP1234583A1 (en) 2001-02-23 2002-08-28 F. Hoffmann-La Roche Ag PEG-conjugates of HGF-NK4
US7713932B2 (en) 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6828305B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7312192B2 (en) * 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US7166571B2 (en) * 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US6913903B2 (en) * 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7196059B2 (en) * 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
PL214862B1 (pl) 2001-10-22 2013-09-30 Amgen Sposób in vitro do okreslania predyspozycji pacjenta ludzkiego z lipoatrofia do reagowania na leczenie bialkiem leptyny, kompozycje farmaceutyczne do zastosowania do leczenia lipoatrofii i kompozycje farmaceutyczne zawierajace bialko leptyny
US20040018959A1 (en) * 2002-05-02 2004-01-29 Randall S. Hickle System and methods of lipid removal from the body
EP1675608B1 (en) 2003-09-12 2007-03-21 Wyeth Injectable calcium phosphate solid rods for delivery of osteogenic proteins
NZ553263A (en) 2004-07-19 2010-06-25 Biocon Ltd Insulin-oligomer conjugates, formulations and uses thereof
US8227408B2 (en) * 2005-09-07 2012-07-24 Neurotez, Inc. Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology
US8716220B2 (en) * 2005-09-07 2014-05-06 Nikolaos Tezapsidis Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amyloid beta
WO2009050738A2 (en) * 2007-10-16 2009-04-23 Biocon Limited An orally administerable solid pharmaceutical composition and a process thereof
CA2725143A1 (en) * 2008-05-21 2009-11-26 Neurotez, Inc. Methods for treating progressive cognitive disorders related to neurofibrillary tangles
US20120071401A1 (en) 2009-04-10 2012-03-22 Amylin Pharamaceuticals, Inc. Amylin agonist compounds for estrogen-deficient mammals
DK3241558T3 (da) 2010-09-28 2021-04-26 Aegerion Pharmaceuticals Inc Højopløselige leptiner
AU2012210624A1 (en) 2011-01-26 2013-07-11 Novo Nordisk A/S Leptin derivatives
WO2021113434A1 (en) * 2019-12-03 2021-06-10 Rodan & Fields, Llc Peptides and compositions for inhibiting hair growth

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4199337A (en) * 1978-10-06 1980-04-22 International Telephone And Telegraph Corporation Method of fabricating high strength optical preforms
US4666836A (en) * 1981-01-02 1987-05-19 The Research Foundation Of State University Of New York Novel cloning vehicles for polypeptide expression in microbial hosts
DE3380726D1 (en) * 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US4757013A (en) * 1983-07-25 1988-07-12 The Research Foundation Of State University Of New York Cloning vehicles for polypeptide expression in microbial hosts
US4643969A (en) * 1983-07-25 1987-02-17 The Research Foundation Of State University Of New York Novel cloning vehicles for polypeptide expression in microbial hosts
EP0154316B1 (en) * 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
AU3329895A (en) * 1994-08-17 1996-03-07 Rockefeller University, The Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5861485A (en) * 1994-08-23 1999-01-19 Millennium Pharmaceuticals, Inc. Polypeptides involved in body weight disorders, including obesity
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5827734A (en) * 1995-01-20 1998-10-27 University Of Washington Materials and methods for determining ob protein in a biological sample
US5567803A (en) * 1995-01-31 1996-10-22 Eli Lilly And Company Anti-obesity proteins
US5580954A (en) * 1995-01-31 1996-12-03 Eli Lilly And Company Anti-obesity proteins
US5563243A (en) * 1995-01-31 1996-10-08 Eli Lilly And Company Anti-obesity proteins
US5594104A (en) * 1995-01-31 1997-01-14 Eli Lilly And Company Anti-obesity proteins
US5559208A (en) * 1995-01-31 1996-09-24 Eli Lilly And Company Anti-obesity proteins
US5569743A (en) * 1995-01-31 1996-10-29 Eli Lilly And Company Anti-obesity proteins
US5554727A (en) * 1995-01-31 1996-09-10 Eli Lilly And Company Anti-obesity proteins
WO1996023515A1 (en) * 1995-01-31 1996-08-08 Eli Lilly And Company Anti-obesity proteins
US5563245A (en) * 1995-01-31 1996-10-08 Eli Lilly And Company Anti-obesity proteins
US5574133A (en) * 1995-01-31 1996-11-12 Eli Lilly And Company Anti-obesity proteins
US5569744A (en) * 1995-01-31 1996-10-29 Eli Lilly And Company Anti-obesity proteins
US5567678A (en) * 1995-01-31 1996-10-22 Eli Lilly And Company Anti-obesity proteins
US5563244A (en) * 1995-01-31 1996-10-08 Eli Lilly And Company Anti-obesity proteins
AU5539596A (en) * 1995-04-06 1996-10-23 Amylin Pharmaceuticals, Inc. Anti-obesity agents
WO1996040912A1 (en) * 1995-06-07 1996-12-19 Amgen Inc. Ob protein compositions and method
AU1406497A (en) * 1995-12-06 1997-06-27 Schering Corporation Mutational variants of mammalian ob gene proteins
DE69632546T2 (de) * 1995-12-27 2005-06-30 Genentech, Inc., South San Francisco Ob proteinderivate mit verlängerter halbwertzeit

Also Published As

Publication number Publication date
DE741187T1 (de) 1997-04-30
SV1996000030A (es) 1999-01-14
SG49337A1 (en) 1998-05-18
CZ129796A3 (en) 1997-01-15
KR960041194A (ko) 1996-12-19
HU220093B (hu) 2001-10-28
BG62975B1 (bg) 2000-12-29
TW464655B (en) 2001-11-21
JPH093098A (ja) 1997-01-07
UY24219A1 (es) 2001-03-16
HUP9601120A2 (en) 1996-11-28
MX9601655A (es) 1997-07-31
SK56996A3 (en) 1997-04-09
RO117177B1 (ro) 2001-11-30
MY132189A (en) 2007-09-28
HUP9601120A3 (en) 1999-07-28
BG100558A (bg) 1997-03-31
CA2175298A1 (en) 1996-11-06
TNSN96066A1 (fr) 2005-03-15
KR100219970B1 (ko) 1999-10-01
IL118059A0 (en) 1996-08-04
OA10362A (fr) 2001-11-15
AU5197896A (en) 1996-11-14
HU9601120D0 (en) 1996-06-28
JP3244627B2 (ja) 2002-01-07
EP0741187A3 (hu) 1996-12-11
TR199600357A2 (tr) 1996-11-21
YU26596A (sh) 1999-03-04
NZ286466A (en) 1998-03-25
ES2093593T1 (es) 1997-01-01
MA23856A1 (fr) 1996-12-31
AU688210B2 (en) 1998-03-05
BR9602166A (pt) 1998-01-13
HRP960213A2 (en) 1997-10-31
US6025325A (en) 2000-02-15
RU96109211A (ru) 1998-10-27
CN1157290A (zh) 1997-08-20
AR003087A1 (es) 1998-07-08
PL314051A1 (en) 1996-11-12
NO961796D0 (no) 1996-05-03
PE50897A1 (es) 1997-12-19
GR960300075T1 (en) 1996-12-31
EP0741187A2 (en) 1996-11-06
NO961796L (no) 1996-11-06
PL186568B1 (pl) 2004-01-30

Similar Documents

Publication Publication Date Title
IS4343A (is) Einstofna offitu (Ob) prótín
DE69627026D1 (de) Osteosynthesevorrichtung
DE59608254D1 (de) Osteosynthesevorrichtung
DE69529921D1 (de) Bewegungsunterstütztes weiterreichungsverfahren
DE69634279D1 (de) Verbinder
TR199600084A2 (tr) Sismanlamaya karsi proteinler.
DK0748583T3 (da) Mejetærsker
DE69528180D1 (de) Modifiziertes molkeprotein
NO976058L (no) Rekombinant mistellectin
BR9610239A (pt) Proteínas de fusão-alérgeno-xcd32
DE69634637D1 (de) Münzausgabevorrichtung
BR9609671A (pt) Amino uracilas substituídas
FI972763A (fi) Mutanttiproteiineja
DE69607261D1 (de) Anschlussbrücke
DE69621746D1 (de) Verbinder
BR9606756A (pt) Peptídeo
NO981052D0 (no) Peptidderivater
DE69603897D1 (de) Verbinder
DE59608566D1 (de) Rektoskop
NO981051D0 (no) Peptidderivater
KR960026478U (ko) 골절기
DE69615048D1 (de) Silikonpseudogel
DE69621586D1 (de) Osteosynthesehilfsmittel
KR960030462U (ko) 콘돔
KR970011600U (ko) 보안경